{"corpus_id":767946,"paper_sha":"d1e43a4fbd106fa2d649f7d2f3353225ebe241e1","doi":"10.1038/nature11159","arxiv_id":null,"pmid":22722194,"pmcid":"3383642","mag_id":2070789802,"dblp_id":null,"acl_id":null,"title":"Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets","year":2012,"publication_date":"2012-04-27","venue":"Nature","journal":{"name":"Nature","pages":"361 - 367","volume":"486"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Chemistry","Medicine","Computer Science","Biology"],"reference_count":70,"citation_count":802,"influential_citation_count":14,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Blood Platelets","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D001792"},{"d":"Chlorotrianisene","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D002741"},{"d":"Cyclooxygenase 1","mj":false,"qs":[{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D051545"},{"d":"Cyclooxygenase Inhibitors","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D016861"},{"d":"Databases, Factual","mj":false,"ui":"D016208"},{"d":"Drug Evaluation, Preclinical","mj":false,"qs":[{"q":"methods","mj":true,"ui":"Q000379"}],"ui":"D004353"},{"d":"Drug-Related Side Effects and Adverse Reactions","mj":true,"ui":"D064420"},{"d":"Estrogens, Non-Steroidal","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D004968"},{"d":"Forecasting","mj":false,"ui":"D005544"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Models, Biological","mj":false,"ui":"D008954"},{"d":"Molecular Targeted Therapy","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D058990"},{"d":"Platelet Aggregation","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D010974"},{"d":"Reproducibility of Results","mj":false,"ui":"D015203"},{"d":"Substrate Specificity","mj":false,"ui":"D013379"},{"d":"Toxicity Tests","mj":false,"qs":[{"q":"methods","mj":true,"ui":"Q000379"}],"ui":"D018675"}],"chemicals":[{"n":"Cyclooxygenase Inhibitors","ui":"D016861","reg":"0"},{"n":"Estrogens, Non-Steroidal","ui":"D004968","reg":"0"},{"n":"Chlorotrianisene","ui":"D002741","reg":"6V5034L121"},{"n":"Cyclooxygenase 1","ui":"D051545","reg":"EC 1.14.99.1"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Discovering the unintended ‘off-targets’ that predict adverse drug reactions is daunting by empirical methods alone. Drugs can act on several protein targets, some of which can be unrelated by conventional molecular metrics, and hundreds of proteins have been implicated in side effects. Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended ‘side-effect’ targets. Approximately half of the predictions were confirmed, either from proprietary databases unknown to the method or by new experimental assays. Affinities for these new off-targets ranged from 1 nM to 30 μM. To explore relevance, we developed an association metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug–target–adverse drug reaction network. Among these new associations was the prediction that the abdominal pain side effect of the synthetic oestrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1. The clinical relevance of this inhibition was borne out in whole human blood platelet aggregation assays. This approach may have wide application to de-risking toxicological liabilities in drug discovery.","claims":[{"public_id":"cl_f7f410652b186c145a2ad6821f73ecbf","status":"active","text":"A computational strategy predicted the activity of 656 marketed drugs on 73 unintended side-effect targets.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f7f410652b186c145a2ad6821f73ecbf"},{"public_id":"cl_fb3cbc9374851d0f99dbe122f3744252","status":"active","text":"An association metric was developed to prioritize new off-targets that explained side effects better than any known target of a given drug, and these associations were organized into a drug–target–adverse drug reaction network.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_fb3cbc9374851d0f99dbe122f3744252"},{"public_id":"cl_6ae80c7d0b3ff303f058e559bd1cd3e7","status":"active","text":"Approximately half of the predicted drug–target activities were confirmed by proprietary database evidence or new experimental assays.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6ae80c7d0b3ff303f058e559bd1cd3e7"},{"public_id":"cl_f18499586fab7c84921167466b52fdeb","status":"active","text":"The abdominal pain side effect of chlorotrianisene was predicted to be mediated by inhibition of cyclooxygenase-1, and this inhibition was supported by whole human blood platelet aggregation assays.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f18499586fab7c84921167466b52fdeb"},{"public_id":"cl_10791a4fb6982f4be8cee6aed208037a","status":"active","text":"The newly confirmed off-target affinities ranged from 1 nM to 30 μM.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_10791a4fb6982f4be8cee6aed208037a"}],"concepts":[{"public_id":"co_07cada1a100f53eaa1e54d967b3cc7b1","status":"active","name":"whole human blood platelet aggregation assays","description":"Functional assays performed in human blood to test platelet aggregation effects.","types":["bioassay"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_07cada1a100f53eaa1e54d967b3cc7b1"},{"public_id":"co_290f5a8a559104e703a43ba66da860cf","status":"active","name":"73 unintended side-effect targets","description":"A collection of protein targets associated with drug side effects and evaluated as off-targets.","types":["protein target set"],"aliases":["side-effect targets","off-targets"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_290f5a8a559104e703a43ba66da860cf"},{"public_id":"co_33c4e0d27c1a260d1eda96f9e7ae79c8","status":"active","name":"association metric","description":"A scoring measure developed to rank off-target associations by their ability to explain side effects.","types":["metric"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_33c4e0d27c1a260d1eda96f9e7ae79c8"},{"public_id":"co_39956b8778f10259d29334aee8a34350","status":"active","name":"predicted drug–target activities","description":"Computationally inferred interactions between drugs and unintended protein targets.","types":["prediction"],"aliases":["predictions"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_39956b8778f10259d29334aee8a34350"},{"public_id":"co_5d891f75468eeed3f5b0c865d19e8c44","status":"active","name":"proprietary databases","description":"Private databases used as an external source to confirm predicted activities.","types":["database"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5d891f75468eeed3f5b0c865d19e8c44"},{"public_id":"co_904a890452db67ba46098e1f42f27d3b","status":"active","name":"656 marketed drugs","description":"The set of approved drugs analyzed for predicted activity on side-effect targets.","types":["drug set","analysis cohort"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_904a890452db67ba46098e1f42f27d3b"},{"public_id":"co_9bc494e96f47bd283bd330f3ee70cc5f","status":"active","name":"new off-targets","description":"Previously unrecognized unintended protein targets identified for marketed drugs.","types":["protein target"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9bc494e96f47bd283bd330f3ee70cc5f"},{"public_id":"co_b3da0a4c90b14aa9ac6d45f212c84b56","status":"active","name":"drug–target–adverse drug reaction network","description":"A network linking drugs, their targets, and adverse drug reactions.","types":["network"],"aliases":["drug-target-ADR network"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b3da0a4c90b14aa9ac6d45f212c84b56"},{"public_id":"co_b765e745a10a3f18e5fb923b0aac5586","status":"active","name":"off-target affinities","description":"Binding strengths of drugs for unintended protein targets.","types":["measurement"],"aliases":["affinities"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b765e745a10a3f18e5fb923b0aac5586"},{"public_id":"co_c0a107598f83c52064916bdfbfd93e39","status":"active","name":"computational strategy","description":"A computational approach used to predict drug activity against unintended protein targets.","types":["method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c0a107598f83c52064916bdfbfd93e39"},{"public_id":"co_c1f2206928012f7cb5d442b579029b5d","status":"active","name":"experimental assays","description":"Laboratory tests used to validate predicted drug–target interactions.","types":["validation assay"],"aliases":["new experimental assays"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c1f2206928012f7cb5d442b579029b5d"},{"public_id":"co_d258b68aa10a3cba239c6987f1b8c6d7","status":"active","name":"cyclooxygenase-1","description":"An enzyme identified here as a newly discovered inhibition target of chlorotrianisene.","types":["enzyme","protein target"],"aliases":["COX-1"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d258b68aa10a3cba239c6987f1b8c6d7"},{"public_id":"co_fe90355df32f01f5dd6b5e7fc95b7fcc","status":"active","name":"chlorotrianisene","description":"A synthetic oestrogen drug used as an example of an off-target side-effect association.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fe90355df32f01f5dd6b5e7fc95b7fcc"}],"external_ids":{"DOI":"10.1038/nature11159","ArXiv":null,"PubMed":22722194,"PubMedCentral":"3383642","MAG":2070789802,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/767946","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":635729,"paper_uid":"8116349f-fb77-4e79-a65a-cda39051813d","canonical_identity":{"paper_id":635729,"paper_uid":"8116349f-fb77-4e79-a65a-cda39051813d","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/767946"}